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Abstract
Background: The present study assessed malaria RDT kits for adequate and correct packaging, design and
labelling of boxes and components. Information inserts were studied for readability and accuracy of information.
Methods: Criteria for packaging, design, labelling and information were compiled from Directive 98/79 of the
European Community (EC), relevant World Health Organization (WHO) documents and studies on end-users’
performance of RDTs. Typography and readability level (Flesch-Kincaid grade level) were assessed.
Results: Forty-two RDT kits from 22 manufacturers were assessed, 35 of which had evidence of good manufacturing
practice according to available information (i.e. CE-label affixed or inclusion in the WHO list of ISO13485:2003 certified
manufacturers). Shortcomings in devices were (i) insufficient place for writing sample identification (n = 40) and (ii)
ambiguous labelling of the reading window (n = 6). Buffer vial labels were lacking essential information (n = 24) or
were of poor quality (n = 16). Information inserts had elevated readability levels (median Flesch Kincaid grade 8.9,
range 7.1 - 12.9) and user-unfriendly typography (median font size 8, range 5 - 10). Inadequacies included (i) no
referral to biosafety (n = 18), (ii) critical differences between depicted and real devices (n = 8), (iii) figures with
unrealistic colours (n = 4), (iv) incomplete information about RDT line interpretations (n = 31) and no data on test
characteristics (n = 8). Other problems included (i) kit names that referred to Plasmodium vivax although targeting a
pan-species Plasmodium antigen (n = 4), (ii) not stating the identity of the pan-species antigen (n = 2) and (iii) slight
but numerous differences in names displayed on boxes, device packages and information inserts. Three CE labelled
RDT kits produced outside the EC had no authorized representative affixed and the shape and relative dimensions of
the CE symbol affixed did not comply with the Directive 98/79/EC. Overall, RDTs with evidence of GMP scored better
compared to those without but inadequacies were observed in both groups.
Conclusion: Overall, malaria RDTs showed shortcomings in quality of construction, design and labelling of boxes,
device packages, devices and buffers. Information inserts were difficult to read and lacked relevant information.
Background
The use of malaria RDTs is rapidly expanding
Prompt parasitological confirmation by microscopy or
alternatively by RDTs is recommended in all patients
suspected of malaria before treatment is started [1].
As a consequence, malaria rapid diagnostic tests (RDTs)
are increasingly used as a diagnostic tool in both malaria
endemic and non-endemic settings: in 2007, more than
70,000,000 tests were performed [2].
Malaria RDTs are so-called immunochromatographic
tests that detect Plasmodium antigens in the blood by
an antigen-antibody reaction on a nitrocellulose strip.
The antigen-antibody complex is conjugated to colloidal
gold, and a positive result is visible as a cherry- or pur-
ple-red coloured line. Apart from a control line, there
are one, two or three test lines: the so-called two-band
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a r em o s t l yd e s i g n e dt od i a g n o s ePlasmodium falci-
parum. Their targets are either histidine-rich protein-2
(HRP-2) or P. falciparum-specific parasite lactate dehy-
drogenase (Pf-pLDH). Three-band RDTs display a
second test line mostly targeting antigens common to
the four species such as pan-Plasmodium-specific para-
site lactate dehydrogenase (pan-pLDH) or aldolase. The
four-band RDTs have an additional third test line target-
ing Plasmodium vivax-specific pLDH (Pv-pLDH).
Written instructions add to the correct performance and
interpretation of RDTs
RDTs are accurate and robust but they have limitations
linked to design, production and distribution [3-8]. In
addition, there are errors at the level of the end-user,
which apply to both laboratory staff and field workers
and are related to sampling, testing and interpretation
of RDTs [9,10]. Clearly written instructions can add to
the comprehensibility and maximize RDT kit perfor-
mance [9,10]. On this basis, the World Health Organiza-
tion (WHO) designed easy-to-read generic job aids [11].
During field visits in Africa, teams of the Institute of
Tropical Medicine (ITM) occasionally noted shortcom-
ings in RDT kit boxes, content and instructions. In addi-
tion, part of the interpretation errors that were observed
during a recent external quality assessment (EQA) on
RDTs were shown to be related to errors in the infor-
mation inserts of the RDT kits used [4]. Inspection of
these information inserts also revealed a large variety in
layout and readability, as well as variations in the ade-
quacy of labelling of RDT boxes and devices.
Objectives of the present study
In view of the observations above, it was decided (i) to
assess malaria RDT kits for adequate and correct design,
construction and labelling of boxes and components,
and (ii) to study the readability and accuracy of their
information inserts.
Methods
Selection of RDT kits
Malaria RDTs marketed as devices consisting of cas-
settes, cardboard boxes and hybrids (nitrocellulose strips
to be dipped into plastic wells) were selected. They were
checked for the presence of the CE label and evidence
of good manufacturing practice (GMP) based on their
inclusion in the WHO lists of RDT manufacturers and
distributors complying with ISO13485:2003 or US FDA
21 CFR 820 production norms [12].
As this study was not intended to score RDTs indivi-
dually, it was decided not to display the RDT brand and
kit names, in line with previous comparative studies
assessing RDTs [3-5,13].
Criteria used for RDT kit assessment and procedure
For packaging, design and labelling, assessment criteria
were compiled from requirements listed in regulatory
documents such as the Directive 98/79/EC and the
European Community (EC) as well as relevant WHO
documents [14-17]. Criteria for information inserts and
device design from studies on end-users’ performance
and RDT instructions were pooled [5,7,9,10,18-24].
Inadequacies were defined as listed in Table 1.
RDT kit package, device package, device and buffer vial
The RDT kit packages were assessed for type (box ver-
sus plastic bag), material (simple and plasticized card-
board) and the presence and quality of the printed
information. Information displayed on the package con-
sidered as essential included the RDT kits and manufac-
turer’s names, expiry date, number of tests included,
storage requirements and a reminder to read the
instructions before use. A referral to the intended use
of the RDT kit was looked for, either by the RDT kit
name or by an additional text. The expiry date men-
tioned on the box was matched with those of the other
RDT kit components. For CE labelled RDT kits pro-
duced by companies outside the European Economic
Area, the affixing of the so-called authorized representa-
tive of the company in the EC (EC-REP) was assessed.
Kits were assessed for sampling material needed
included or not.
The package of the test device was checked for quality
(humidity-proof material) and essential information
including RDT kit name, lot number and expiry date. In
addition, the desiccant was checked for composition,
warning label and presence of colour indicator.
The RDT devices (cassette or cardboard housing the
nitrocellulose strip) were assessed for clearness of design
and construction including referral to the RDT kit’s
name. The space allocated for sample identification was
evaluated for dimensions and ease of writing. A space of
minimal 0.5 cm height and 4 cm wide was considered as
adequate for handwriting of sample identification. The
labelling of buffer wells, sample wells and reading win-
dows including the places of appearance of the control
and test lines (further referred to as reading label) were
assessed for visibility and unambiguous interpretation.
The buffer vials were assessed for leak-proof closure,
and their labels for quality of adherence and print. The
information displayed on the label was assessed for the
presence of RDT kit name, lot number, expiry date and
storage conditions.
RDT information insert
RDT kits were checked for the presence of an informa-
tion insert and a job aids (short procedure version), of
which date of release and version number were assessed.
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The figures were counted and their dimensions mea-
sured. Their total surface area was calculated and
expressed as a percentage of the total surface of the
information insert. The figures were assessed for their
concept (pure black and white versus use of colours)
and conformity with the real devices.
Typography
The font size of the predominant letter type used
(excluding the bibliography section) was measured in
Cicero using a typometer (Rotring-werke Riepe KG,
Hamburg, Germany) as the “kp” distance from the top
of the highest ascender (top of the lower case letter k)
to the bottom of the lowest descender (bottom of the
lower case letter p). The opening of the characters was
visually assessed for the characters “c, o and a”,b yc o v -
ering them for their lower two-thirds and checking
whether they were still correctly readable (open letter
type) versus read as an “o” (closed letter type). The
interline spacing was assessed by measuring in Cicero
w i t hat y p o m e t e rt h ed i s t a n c eb e t w e e nt h eb a s el i n eo f
two successive rows and then subtracting the font size.
Table 1 Number of RDTs (n = 42) with inadequacies in malaria RDT boxes, device packages, devices, buffer vials and
package inserts*
Items considered to be inadequate Number (%)
Box: construction and design
Materials: plastic bag or simple cardboard (not humidity-resistant) 9 (21.4)
No labels, no printed information or labels not humidity-resistant 6 (14.3)
Differences in name on device packaging, device, buffer and information insert 27 (64.3)
Box: information displayed
No EC-REP mentioned on CE labelled RDTs, although required (n = 25) 3 (12.0)
RDT kit’s name nor additional information refer to intended use 3 (7.1)
RDT kit’s name incorrectly refers to P. vivax instead of non-falciparum species (n = 29) 4 (13.8)
Kit components not displayed 26 (62%)
Essential information lacking: expiry date, numbers of tests included, storage conditions 12 (28.6)
Kit contents:
Capillary sampling system (lancet and alcohol swap) not included or not optionally included 24 (57%)
Blood transfer system (capillary, pipette or tube) not included 3 (7.1%)
Device package and content: construction and design
Material not humidity-resistant 4 (9.5)
No desiccant or desiccant without saturation indicator 18 (42.9)
Device package and content: information displayed
Essential information lacking: expiry date, lot number, test kit name 9 (21.4)
No warning label “do not swallow” on desiccant 6 (14.3)
Device: construction and design
Space for sample identification too small or not writable with standard pen (felt pen needed) 40 (95.2)
No or incomplete RDT name on the device 29 (69.0)
No reading label or simultaneous presence two reading labels consisting of symbols only 6 (14.3)
Buffer: construction and design
Buffer vial not leak proof 2 (4.8)
Label does not stick well to the vial, prints are not humidity-resistant (n = 40) 16 (40.0)
Buffer: information displayed
Essential information lacking: expiry date, lot number, storage conditions, correct RDT kit’s name (n = 41) 24 (58.5)
No instructions included on how to pierce the buffer vial dropper (n = 15) 5 (33.3)
Package insert: information
Absence of date of release or version number 20 (47.6)
Package insert: content
Identity of target antigens not clearly mentioned 2 (4.8)
No referral to biosafety precautions (gloves, safe waste disposal, etc.) 18 (42.9)
Major differences between depicted and real device (n = 40) 8 (20.0)
Use of figures with unrealistic colours (e.g. control and test lines depicted as green) 4 (9.5)
No data on test characteristics (sensitivity, specificity) 8 (19.0)
*Total number of RDT kits = 42 unless otherwise stated.
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larger than 2 are better readable compared to fonts of
closed letter types and interline spacing smaller than 2,
especially at larger text columns. For patient education
materials and health instructions, font sizes of 12 or lar-
ger are recommended [25,26].
Readability level
For assessment of the readability level, the sessions
about blood sampling, procedure and interpretation in
the English text version were copied or retyped in
Microsoft Word (Microsoft Corp., Redmond, WA,
U.S.A.) and checked for correct spelling and syntax con-
struction. Follow-up editing was performed as described
elsewhere [27]. Next, the text fragments were copied
into an on-line readability assessment tool, which gener-
ates different reading indices [28]. The Flesch-Kincaid
grade level [29] was calculated. This grade-level
expresses the U.S. grade-level equivalency of the skills
required to read a particular document. For patient edu-
cation materials and health related information, the
recommended level is ≤ 6
th grade level [25,30].
Accuracy and relevance of information
The following items were actively looked for: description
of the RDT test principle, target antigens, listing of
required materials provided and not, description of sam-
pling procedures and biosafety precautions. The RDT
test procedures were studied with reference to common
errors made by end-users in the field (Table 2)
[5,9-11,18,19,23]. The interpretation section was
assessed for the complete description of invalid results
and Plasmodium species differentiation as well as for
listing causes of false negative and false positive results.
The description of test characteristics was assessed for
mentioning the diagnostic accuracies related to the dif-
ferent Plasmodium species and parasite densities. Biblio-
graphic references were checked for relevance with
regard to RDT performance in general and information
on the RDT kit’s performance in particular.
Assessment, data registration and statistical analysis
Two observers trained in the use of RDTs independently
assessed the RDTs according to the described criteria.
Discrepant observations were discussed together with
the other investigators and a consensus was reached.
Data were registered in an Excel sheet (Microsoft Corp.,
Redmond, WA, U.S.A.).
Results
Panel of RDT kits
For the purpose of this study, 51 RDT kits were ordered
at 29 companies. Seven companies (representing nine
RDT kits) did not reply despite several reminders. The
final panel consisted of 42 RDT kits from 22 companies.
Nearly all (39/42, 93%) RDT kit formats were cassettes,
further there were one cardboard and two hybrid kits.
Two RDT kits consisted of individually wrapped RDT
packages containing all materials for a single test (cas-
sette, disinfectant, lancet and buffer). They will be
further referred to as “Single RDT kits”. Table 3 lists the
RDTs according to their evidence of GMP. Table 1 lists
the number of the RDTs with inadequacies in boxes,
devices, buffer vials and information inserts.
RTD kit package, device and buffer vial
RDT kit package
Thirty-eight RDT kits arrived as cardboard boxes; four
kits arrived in plastic bags. Two of these plastic bags
contained a cardboard box to be folded by the end-user,
resulting in a total of 40 boxes and two plastic bags as
the package of use on the bench. All but one box dis-
played an indication in the RDT kit’sn a m eo ri nt h e
test description that the RDT kit was intended for
malaria diagnosis. The two plastic bags did not display
Table 2 Number of RDT information inserts (n = 40)
addressing critical steps in procedure and interpretation
Items addressed in procedure section Number
(%)
Bring the RDT device and buffer to room temperature 32 (80.0)
Check the integrity of the device package 9 (22.5)
Check expiry date 27 (67.5)
Use the device immediately after opening 28 (70.0)
Place the device on a level surface 0 (0.0)
Check the desiccant for signs of exposure to humidity 11 (27.5)
Write down sample identification 3 (7.5)
Wipe finger with alcohol 26 (65.0)
Allow the finger to dry before pricking 12 (30.0)
Hold the transfer device (loop, straw) vertical 8 (20.0)
Hold the buffer vial vertical 12 (30.0)
Do not to use another buffer than the one provided with
the kit
9 (22.5)
Use an adequate light source for reading 3 (7.5)
Items addressed in interpretation section Number
(%)
All possible line combinations for invalid test results are
mentioned
12 (30.0)
All possible test line combinations for positive test results
are mentioned
31 (77.5)
Interpretation of a faint test line as positive is mentioned 8 (20.0)
Causes of false negative results are mentioned, in particular
low parasite densities
11 (27.5)
Causes of false positive results are mentioned, e.g. presence
of the rheumatoid factor
3 (7.5)
Persistence of HRP-2 is mentioned 19 (47.5)
To repeat the test in case of a negative RDT result and
persistent suspicion of malaria is mentioned
1 (2.5)
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40 boxes, but for 12 kits, it was not clearly mentioned
whether this name represented the manufacturer or the
distributor.
T h el o tn u m b e ra n de x p i r yd a t ew e r el i s t e do na l l
boxes. One of the Single RDT kits showed both lot
number and expiry date on the outer box containing the
single packages, but not on the single packages them-
selves. There were no discrepancies between the expiry
dates on the RDT kit box and those of the contents
except for two buffer vials with expiry dates extending
those printed on the RDT kit box.
The number of tests included and a reminder to read
the instructions before use were not displayed on four
and ten boxes respectively. All the 40 boxes showed
information on storage temperature requirements, by
written text, symbols or both. Apart from a single sym-
bol, i.e. a penguin expressing “do not freeze”, all symbols
were internationally recognized symbols complying with
EN 980:2008 or FDA 2004, 21 CFR 809.10 and 21 CFR
Parts 610 and 660. Capillary blood sampling systems
were included in eight kits and proposed as optional in
ten other kits. Blood transfer systems were missing in
three kits.
Device packages
Four of 42 device packages were not made of humidity-
resistant material. Most of the packages were easy to
open by tearing a pre-cut lid of the package. However,
for three packages, scissors had to be used to open the
packages properly.
A desiccant was present in all but one package. Three
of the 41 desiccants did not show a warning that
the desiccant was harmful: two of them (from one man-
ufacturer) were tablets looking like drug pills. Seventeen
desiccants (including the two tablets) had no colour
indicator of humidity saturation.
RDT devices
Space for writing was too small in 40 of the 42 devices
(Figure 1). For two cassettes, a felt pen was required as
a standard pen failed to mark.
Most cassettes (35/39) had separate wells for sample
and buffer application, four had a single well for sample
and buffer application. There was no uniform labelling of
the wells: for instance characters “S” and “A” were used
randomly for the sample well, buffer well and combined
sample/buffer well (Figure 2). Fifteen cassettes showed at
the distal end a window or holes that might be confused
with a sample or buffer well (Figures 1 and 2).
The reading label was indicated with acronyms (n = 20),
characters or numbers. Acronyms included abbreviations
such as “Pf” or “pan”,t h e yw e r ep r i n t e do nt h ep l a s t i c
housing or on a label and were well readable. Characters
such as “C” (control line) and “T” and numbers were
embedded in the plastic housings and were more difficult
to distinguish (Figure 2). In one cassette, characters were
printed on a label, which was not well fixed (Figure 1). In
14 cassettes, two labels were displayed at either side of the
reading window (Figure 2), and one three-band cassette
had no reading label at all (Figure 2).
RDT buffer vials
The two Single kit RDTs contained a small buffer plastic
ampoule in each device package, which were too small
to display information. Fifteen buffer vials required
clockwise tightening the vial cap to pierce the dropper
vial nozzle, but for five of them, this was not mentioned
in the information insert. For 13 vials, the label was not
well fixed and the printed information on three of these
labels was not humidity-resistant. Lot number and
expiry date were not listed on five vials and storage con-
ditions were missing on 10 vials.
Table 3 Overview of the RDT kits evaluated in the
present study
Evidence of GMP
RDT
format
Plasmodium antigens
targeted
Number CE
mark
WHO
list
†
Total
Two
band
HRP-2 7 4 5 7
pan-pLDH 1 1 0 1
Pv-pLDH 1 1 0 1
Three
band
HRP-2, pan-pLDH 11 5 7 9
HRP-2, aldolase
‡ 55 *5 5
HRP-2, Pv-pLDH 4 1 1 2
Pf-pLDH, pan-pLDH 6 5 6 6
Four
band
HRP-2, Pv-pLDH, pan-
pLDH
735 6
*One three-band test (HRP-2, aldolase) is FDA approved.
†WHO list of ISO:13485:2003 certified manufacturers and their RDT products
(list of known commercially available antigen detecting malaria RDTs) [12].
‡One of these RDTs used both aldolase and pan-pLDH as pan-malarial
antigen.
Figure 1 Four-band RDT. The allocated place for writing sample
identification is too small. The grid at the left hand may be
confused with a sample well. There are two different reading labels
at each side of the reading window, of which the lower one is
printed on a label that is not well fixed.
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The information inserts of the two Single RDT kits were
not considered: one of them contained a simple job aids
explaining the procedure by figures only, the other con-
tained a shortened version of the information insert of
the same RDT marketed as laboratory kit. All of the
remaining 40 RDT kits contained an information insert
of which seven had an additional job aids. Either version
number or date of issue was missing in 11 and 13 of
them; in five, both were missing.
Layout and figures
All 40 inserts included figures. The median number of
figures per information insert was 8.5 (range 2 - 25) and
figures accounted for a median surface ratio of 7.2%
(range 0.4% - 33%) of the entire insert. The median size of
the figures was 2.4 × 2.0 cm, the smallest and largest figure
measured respectively 1.0 × 0.3 cm and 6.7 × 8.0 cm.
All inserts used figures to illustrate the interpretation
section. Other figures depicted blood sampling (n = 17),
application of sample and buffer (n = 21) and a clock
indicating the correct reading delay (n = 10). Fourteen
inserts used red colour to indicate control and test lines
but in four, they were pictured green or blue. Most
inserts (n = 35) showed differences between depicted
and real devices of which some were major, such as dis-
crepancies between characters used for sample and buf-
fer well identification (n = 4) and differences in labelling
of the reading window (n = 5) (Figures 3 and 4). One
insert mentioned a reading delay of 15 minutes, but the
illustration mentioned a reading delay of 20 minutes
(Figure 5).
Typographic features and readability
Figure 6 displays the font size and line spacing of the
information inserts. Median font size was 8 ± 1.3,
none of them exceeded 10. User-unfriendly typo-
graphic features included combinations of font sizes of
eight or smaller with a closed letter type (n = 10) or
with line spacing lower than two and more than 12
words per line (n = 14) (Figure 7). Median readability
level was grade 8.9 (range 7.1 - 12.9) and 18 and four
of the inserts’ readability levels were above grade 9 and
10 respectively (Figure 8). Readability levels of the job
Figure 2 Example of RDT cassettes. Most of the cassettes have separated wells for sample and buffer application. There is no uniform
labelling of the wells: different characters (e.g. “S”, “A”) are used randomly for the sample well, buffer well and combined sample/buffer well. The
reading labels are indicated with acronyms, characters or numbers.
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six out of seven exceeded the readability level of the
most recent WHO job aids. Five inserts showed prints
of very poor quality hindering reading of the text
(Figure 9).
Accuracy and relevance of information
The RDT kit’s principle was described in all 40 informa-
tion inserts. All but two inserts mentioned the materials
provided in the RDT kit, and seven inserts provided a
complete list of the materials required.
All RDT kit inserts mentioned the required specimen
(in all cases both capillary and venous blood), all but
one mentioned the anticoagulant to be used. Capillary
blood sampling through finger prick was described in 35
inserts, of which one also added sampling by venipunc-
ture. By contrast, the heel prick was not described in
any information insert.
Biosafety precautions included the use of gloves
(depicted or mentioned in 21 inserts, Figure 10) and
safe waste disposal (addressed in 16 inserts), but 18
inserts did not mention any information on biosafety.
From Table 2 it is clear that a number of critical steps
in RDT procedures were addressed by only part of the
RDT inserts. Among them, there were relevant steps
such as writing down sample identification, correct posi-
tioning of the transfer and buffer vial and the need for
an adequate light source.
The complete array of all control and test line combi-
nations was listed by only nine inserts. Fourteen inserts
mentioned the absence of all lines as an invalid result
b u tn o tt h ep r e s e n c eo fat e s tl i n ei nt h ea b s e n c eo fa
control line (Figure 9). In addition, errors in the inter-
pretation of test lines were observed. For instance, the
combination of a Pf-specific and a pan-specific test line
was interpreted as P. falciparum without mentioning the
possibility of a mixed infection (12/34 three- and four-
band RDTs). Likewise, the combination of a Pv-specific
and a pan-specific test line in case of a four-band RDT
was interpreted as a Plasmodium vivax infection without
mentioning the possibility of a mixed infection with
Plasmodium ovale and Plasmodium malariae (6/7
RDTs). In addition, a visible pan-pLDH line was
Figure 3 Interpretation section of the information insert and cassette of a Plasmodium falciparum/Plasmodium vivax RDT.T h er e a l
device has a single sample/buffer whereas the depicted one displays separate wells. The characters used for the reading label on the illustration
are inverted compared to the real device.
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parum species) in two inserts.
Few inserts mentioned causes of false positive and false
negative results (Table 2). One insert recommended to
repeat the test in case of a negative RDT result and per-
sistent suspicion of malaria, another warned about
the prozone effect as a cause of a false negative result
(Figure 4). RDT test results during treatment follow-up
were addressed in 13 inserts, but the information listed
in nine inserts was presented in a scattered way and only
one insert clearly mentioned that HRP-2 persistence does
not indicate a failed therapeutic response.
RDT test characteristics
Eight inserts did not provide information on sensitivity
or specificity. Diagnostic characteristics were mostly
expressed for P. falciparum and P. vivax (n = 31 and
n = 22 respectively), only one insert mentioned test
characteristics for P. ovale and P. malariae. Sensitivity
for P. falciparum was expressed by parasite density
range in 10 inserts.
Bibliography cited in the information inserts
In total, 45 different references were used in the biblio-
graphy of the information inserts. One third of them
referred to the original description of the target antigens,
another 12 referred to general information on malaria
and its diagnosis. Thirteen inserts cited evaluation studies
of RDTs, but only three RDT kits referred to product-
related studies. Two panels of identical references were
shared by nine and eight inserts respectively.
Figure 4 Interpretation section of the information insert and cassette of a P. falciparum/P. vivax RDT. Shape and labels of wells and
reading window are different between the real and the depicted device. Characters are embedded in the plastic housing and poorly
discernable. The text is correct and complete (even the prozone effect and how to deal with it) but less readable (Flesch-Kincaid grade level 9.1).
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Inconsistencies in the RDT kit names and referrals to
target antigens were observed. For instance, four RDT
kits had names referring to P. vivax although they used
a pan-species Plasmodium antigen. Two other inserts
did not mention the identity of the pan-species antigen
(aldolase versus pan-pLDH). Five RDT kits from one
manufacturer were supplied in identical boxes, carrying
the same names and identical prints. Furthermore, there
were slight but numerous differences between names as
displayed on boxes versus those noted on device
packages (eight had no brand name affixed), devices
(15 differences) and information inserts (eight differ-
ences). Similar observations were made for buffer vials:
five vials displayed only the manufacturer’sn a m ea n d
one vial did not show brand nor manufacturer’s name.
RDT kits’ duplicates
During assessment of the RDT kits, apparent similarities
between different RDT brands were observed. These
similarities concerned, amongst others, design and shape
of the device and content and layout of the information
insert (e.g. numbers of samples used for calculation of
test characteristics). In that way, six products were
assumed to represent a common design and production
platform for 16 different RDT brands.
Relation with CE marking and WHO listing
Overall, RDTs with evidence of GMP (n = 35) scored
better compared to those without (n = 5), although
inadequacies, errors and omissions were observed
between both groups. Three CE labelled RDT kits pro-
duced outside European Economic Area (EEA) had no
EC-REP indicated neither on the box nor in the infor-
mation insert. For these kits, the CE symbol as displayed
Figure 5 Information insert of a three-band RDT, procedure
section. There is a discrepancy between the reading time
mentioned in the text compared to that showed on the illustration.
Figure 6 Typographic features of RDT information inserts (n =
40): font sizes and line spacing.
Figure 7 Example of typography used in RDT information
inserts: the package insert on the top is user-unfriendly (font
size 6, line spacing 0,5, close letter type, average number of
words per line 21, Flesch-Kincaid grade 9,5). The package insert
on the background, from the same company but for another RDT
uses a better typography (font size 8, line spacing 2, open letter
type, average number of words per line 14), but the readability is
still elevated (Flesch-Kincaid grade 9,8).
Figure 8 Readability of the RDT information inserts (n = 40)
and job aids (n = 7) expressed as Flesch-Kincaid grade level.
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sions of the 98/79/EC directive (Figure 11). Six of the
eight RDT kits that did not mention data on sensitivity
and specificity were CE labelled.
Discussion
Previous studies demonstrated that RDT manufacturers’
instructions are insufficient to ensure accurate test
performance by community health care workers, and
well-designed instructions such as the WHO generic job
aids have proven to increase performance [9,10,19,31].
In practice however, such job aids still need to be adapted
to the particular RDT brand used on site and, depending
on the chains of supply, different RDT brands and ver-
sions may be available. For market exploration and
choice of RDTs, laboratory managers will orient to RDT
kits’ names and labelling. Clear design and labelling of
RDT kit components will contribute to correct storage
and use; and laboratory staff will rely on RDT inserts for
background information, adaptations of the generic pro-
cedures, interpretation and trouble-shooting.
The design of the present study has its limitations. For
instance, mainly RDTs marketed as cassettes were con-
sidered. However, cassettes are the mostly used platform
and preferred by end-users over the strip format [9].
Besides, only a part of the marketed brands was evalu-
ated; however, this evaluation studied about half of the
80 brands worldwide-marketed [2] including those fre-
quently used in endemic and non-endemic settings.
With regard to the assessment of the information
inserts, it should further be noted that the Flesch-Kincaid
label (as discussed below) is only a proxy measure of
readability. In addition, the layout of the inserts was
assessed for typography but not for other features such
as adequate use of headings, bullets, boldfacing, and
amount of white space [32,33]. Finally, although RDTs
were presently assessed against compiled criteria based
on relevant documents, they were not evaluated by end-
users in a real-life setting. On the other hand, as far as
Figure 9 Interpretation section of the information insert of a
three-band P. falciparum/pan-species RDT. For invalid tests, only
the absence of all lines is mentioned, not the possibility of a visible
test line without a control line. The invalid results are not depicted.
The print quality is poor, no colours are used for the control and
test lines.
Figure 10 Illustration depicting sampling of capillary blood.
The health care worker’s hand is depicted without gloves. The
simultaneous presence of English and French text may be difficult
for a non-experienced reader.
Figure 11 CE-label displayed on a RDT kit box. The shape and
relative dimensions of the characters do not comply with the
requirements as mentioned in the EC Directive 98/79 (depicted in
the insert, upper right corner). There is no authorized representative
(EC-REP) affixed, although required.
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cal devices (IVDs) were assessed for these characteristics.
Problems in design and labelling of the RDT kits’
components
Despite these limitations, much information was gener-
ated on the quality and appropriateness of RDT packa-
ging, labels and inserts. Apart from two exceptions (the
plastic bags), boxes were well labelled, but shortcomings
in labelling of device packages and buffer vials were
more numerous. The absence of blood sampling and
transfer system which was observed in nearly a quarter
of RDT kits may create logistical problems when used
in field settings. The problems in device design were of
most concern. Characters indicating wells and reading
labels that were embedded in the plastic cassette hous-
ings are difficult to distinguish and the simultaneous
presence of two reading labels may cause confusion.
Standardized and unequivocal characters or acronyms
should be used for designating wells and reading labels
and clear labelling with contrasting print should be
ensured.
Some design issues were not compiled from previous
studies but originated from ITM observations. Some of
them may look trivial but have consequences in daily
practice. For instance, device packages without pre-cut
lids require scissors to open, which is neither safe nor
practical in busy and remote settings. The space allo-
cated for sample identification on most cassettes was
large enough for writing down a sample number but not
a patient name: this may meet the requirements in com-
puterized settings but not those in a non-computerized
field setting, where full names are written as recom-
mended by WHO job aids instructions [16]. Likewise, it
is evident that use of a felt pen for writing down sample
identification is inappropriate for a field setting. Another
example was the clockwise tightening of the buffer vial’s
cap for piercing the dropper bottle nozzle: ITM teams
observed that laboratory staff unaware of this procedure
simply cut off the distal end from the nozzle. The
resulting opening tended to be very wide resulting in a
too large volume of buffer added to each test and early
emptying of the buffer vial. The RDT cassettes that
remained without buffer were run with other buffers or
with injection water, at the risk of causing false positive
results [5].
Readability level and typography of the information
insert
The Flesch-Kincaid grade level used in the present study
has been demonstrated to be reliable and valid and is fre-
quently used in health care issues such as consumer medi-
cal information (CMI) and patient education materials
[27,30]. Its use in the present context should be
interpreted with caution. Like any other reading formula,
the Flesch-Kincaid readability tool assesses text structure
but does not take into account the content. It further
refers only to US grade levels and applies to English lan-
guage. Other factors such as motivation and previous
experience may influence comprehension, and linguistic
and cultural issues may interfere [33]. Despite these limita-
tions, it is of note that readability levels of all inserts
exceeded the 6
th grade level, while the recommended level
for health related information is equal or lower than this
level [27,30]. The readability level of the job aids scored
slightly better, but still higher compared to the WHO gen-
eric job aids. Too elevated reading levels have been consis-
tently demonstrated in CMI documents such as those of
home pregnancy tests, blood glucose monitoring and
home blood pressure monitor equipment as well as in
patient education brochures [25-27,32,34,35]. It should
also be taken into account that end-users in endemic set-
tings are likely to be non-native speakers of the language
of the information insert (e.g. English, French, Portuguese),
and may operate in stressful situations such as environ-
mental disasters and war [36,37] which decrease actual
reading levels [38]. Apart from the bad quality prints and
small figures, the observed user-unfriendly typographic
features may add to the decreased readability of the
inserts, which were consistent with those documented for
CMI materials [25,30,32,34,35].
Content of the information insert
The lack of referral to biosafety procedures in nearly
half of the inserts was striking and unacceptable, in par-
ticular because this is clearly mentioned in the WHO
generic job aids [11]. Likewise were the differences
between depicted and real devices and the use of non-
realistic colours for depicting test lines which do not
comply with WHO recommendations [16]. Numbers
and sizes of illustrations did not comply with the estab-
lished standards for patient education materials and
CMI [25,35,39].
The shortcomings in the RDT test interpretation ses-
sion were in line with observations made during a
recent external quality assessment on RDTs in a non-
endemic setting. During that session, not reporting a
mixed infection in case of the simultaneous presence of
P. falciparum- and pan-specific test lines was demon-
strated to be linked to the information inserts of the
RDT kits used [18]. Although extremely rare in the
experience at ITM, the presence of a visible test line in
the absence of a control line points to invalid test
results and should be added to the spectrum of possible
line combinations, preferably with a picture. In addition,
the persistence of HRP-2 after successful treatment and
the production of pLDH by gametocytes should be
clearly mentioned.
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information inserts was another concern. Although cur-
rent directives and recommendations do not specify details
about origin, numbers and statistical validity of these test
characteristics, manufacturers should be encouraged to
provide as detailed and sound data as possible, including
data on sensitivity in relation to parasite density and Plas-
modium species. The low diagnostic sensitivity for
P. malariae and P. ovale is well known [40]: few studies
have included enough samples to provide reliable data for
both species. Those that did mostly found a poor sensitiv-
ity, in particular for P. malariae [40-44]. In the absence of
a thorough evaluation for both species, one could consider
adding a statement mentioning the low overall diagnostic
sensitivity for both species to the information insert, in
order to avoid unrealistic expectations by the end-user
relying on the pan-Plasmodium species nature of the
targeted antigen [40].
The cited bibliography mainly referred to the original
papers on the description of the antigens or general
RDT evaluations. In addition to references addressing
the RDT kit itself, references to one or more of the
r e c e n tr e v i e w so nR D T so rW H O / F I N Dd o c u m e n t s
could be added, as they contain relevant information on
the use and limitations of RDTs.
Names and duplicates of RDTs, relation to GMP and CE
labelling
Among the inadequacies, erratic and inconsistent names
were a frequent finding: they ranged from minor differ-
ences in RDT brand names as displayed on boxes, devices
and their packages and information inserts to brand
names suggesting P. vivax despite using a pan-pLDH tar-
get. In addition, shortcomings with regard to clear speci-
fication of target antigens were noted. For a laboratory
manager finding his way among many other diagnostics
and supplies, it is essential to get a quick and reliable
idea about the intended use and the target antigens of
RDTs. An unequivocal code for naming and short test
descriptions should be considered, with mentioning of
the (abbreviated) antigens as a requisite (e.g.P f - p L D H ,
HRP-2 etc.).
With regard to the presumed RDT kit duplicates (kits
presenting with similar presentation suggesting a shared
design and production), it should be noted that WHO
and FIND recognize this phenomenon [45]. WHO
defines so-called “re-branded” products as products man-
ufactured under identical conditions at the same manu-
facturing site as the original product, but labelled with a
different product name and identifier. WHO encourages,
in such case, joint application for the prequalification
program or test evaluations [45-47]. The CE recognizes
also the “re-branding” for commercial interests. The
coexistence of multiple names for the same product
however may create difficulties for instance in retrieving
published information on test evaluations and may add
to the complexity of post marketing surveillance, includ-
ing traceability in case of batch recalls. To prevent these
problems, the requirement of “re-branded” RDT kits to
mention the original manufacturer should be considered.
I na d d i t i o n ,a n yR D Tk i tl a b e l( w h e t h e ro r i g i n a lo r
re-branded) should clearly distinguish the names of the
manufacturer from that of the local distributor.
Shortcomings and errors were observed among CE-la-
belled and WHO-listed RDTs. Not affixing the EC-REP
when required and not mentioning information on RDT
test characteristics do not conform the 98/79/EC Direc-
tive [48]. It should further be noted that in case of
malaria RDTs, the CE-label by itself is not a guarantee
for intrinsic quality of performance. The 98/79/EC
Directive includes the “Annex II”, which lists diagnostics
for which market release of any new lot has to be pre-
ceded by testing and approval by a competent authority,
the so-called notified body. For diagnostics that are not
listed in the “Annex II” (such as malaria RDTs), such
testing and authorization are not required. Acquisition
of the CE-label for these diagnostics is a purely adminis-
trative process, in which the manufacturer himself
draws up the EC declaration of conformity. Unfortu-
nately, the majority of laboratory and medical staff are
unaware of this procedure. This can create a sense of
“over-confidence” in CE-labelled products, based on the
perception of quality associated with European labels.
The inclusion of RDTs for malaria and other tropical
diseases in the “Annex II” could represent a significant
support for countries with weak regulatory overview.
What can be done to improve the quality of RDT package
and information inserts?
Many shortcomings such as incomplete and incorrect
labelling of boxes, device packages, cassettes and buffer
vials can be easily remediated at minimal costs. End-
users and manufactures should reach consensus on uni-
form codes for labelling wells and reading windows and
gradually reinforce the requirements for inserts and
packaging. Generic recommendations as how to layout
and how to appropriately design information inserts as
well as use of figures can be found in the literature on
CMI [25,35,39], RDT specific guidelines have been
issued by the WHO [16]. Readability, cultural and lin-
guistic backgrounds should be taken into account [23],
and all texts and figures should be assessed for appro-
priateness and comprehension among the targeted end-
users [10,49]. For the content of RDTs, the reference
documents that were used to compile Tables 1 and 2
can give guidance. Examples of such checklists are
added as additional files (Additional file 1 Table S1 and
Additional file 2 Table S2). The information inserts
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pretation in order to reduce the likelihood of potential
errors.
With regard to user-friendliness and adequacy of RDT
presentation and instructions, interesting features not
listed on the compiled criteria were noted. For instance,
some device packages carried short instructions for use
based upon the generic WHO job aids [16], witch may
increase the test performance [9,10,19,31]. The availabil-
ity of job aids for the different brands on the company
websites in an adaptable text format may help Malaria
National Programs to translate it in the end-user lan-
guage and to adapt it on the local context. In addition,
some RDT kits provided a glossary with explanation of
the affixed symbols, which may help in their compre-
hension and acquisition and another five had all essen-
tial information printed on a single (lateral) side of the
box, contributing to easy storage (Figure 12). Another
asset was the presence of more than one buffer vial per
RDT box, as shortage and replacement of buffer vials is
a common problem in resource limited settings [5].
Likewise, the above described observations and correc-
tive measures could be extended to other IVDs, such as
human immunodeficiency virus RDTs.
Of course, it should be noted that adequate packages
and information inserts by themselves are not a guaran-
tee for competent use of RDTs. Simply distributing the
RDTs and instructions does not work, and RDT instruc-
tions on their own will not change professional beha-
viours [20]. Thorough training and performance
monitoring are needed for correct performance [16].
Conclusion
In conclusion, malaria RDTs showed shortcomings with
regard to quality of construction, design and labelling of
boxes, device packages, devices and buffers. Information
inserts were difficult to read and lacked relevant
information. Particular problems were observed in the
consistency and appropriateness of RDT brand names
and in the referral to the antigens used. In general,
CE-labelled and WHO-listed RDTs scored better com-
pared to those without but inadequacies were observed
among these RDTs. Addressing the quality of RTD pack-
age and information inserts in evaluation programs such
as the WHO/FIND products testing program could sti-
mulate the manufacturers to remediate these shortcom-
ings. Likewise, inclusion of malaria RDTs in the “Annex”
II of the 98/79/EC directive might represent a powerful
support from the European Community towards the
quality of in-vitro diagnostics in tropical countries.
Additional material
Additional file 1: Example of operational checklist for packaging,
labelling and instructions of RDTs.
Additional file 2: Example of a checklist for the content of the
information inserts.
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Figure 12 Example of the lateral side of a RDT box: all
essential information is printed on a single side of the box,
contributing to clear storage.
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